Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist

Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. Ho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annales de biologie clinique (Paris) 2003-11, Vol.61 (6), p.645
Hauptverfasser: Parant, F, Ducluzeau, R, Lardet, G, Gagnieu, M-C, Moulsma, M
Format: Artikel
Sprache:fre
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page 645
container_title Annales de biologie clinique (Paris)
container_volume 61
creator Parant, F
Ducluzeau, R
Lardet, G
Gagnieu, M-C
Moulsma, M
description Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_14711605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14711605</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-dac7c5bd2af9c9e45e307a2ca1e82ffe64669626d5fdb86c6ae14a0ad1f34f8b3</originalsourceid><addsrcrecordid>eNo1j81KAzEYAHNQbG19BckLLCSbn816K8WqUOil9_Il-ZJGdpNlN4K-vQftaQ4DA3NH1owx0QjTmxV5XJZPxnhrhHggKy47zjVTa3La5Zp8iuU7ZXoAS8MMccRcFwrZ05sZS061zCnHFwrUXWEYMEekocy0XpHaVIYS01K35D7AsODTPzfkfHg979-b4-ntY787NpOSqvHgOqesbyH0rkepULAOWgccTRsCaql1r1vtVfDWaKcBuQQGngchg7FiQ57_stOXHdFfpjmNMP9cbmPiF1ebSpA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</creator><creatorcontrib>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</creatorcontrib><description>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are &gt;25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</description><identifier>ISSN: 0003-3898</identifier><identifier>PMID: 14711605</identifier><language>fre</language><publisher>France</publisher><subject>Aged ; Aged, 80 and over ; Digoxin - blood ; Digoxin - immunology ; Drug Monitoring - methods ; Female ; Humans ; Immunoglobulin Fab Fragments - therapeutic use ; Male ; Middle Aged ; Ultrafiltration</subject><ispartof>Annales de biologie clinique (Paris), 2003-11, Vol.61 (6), p.645</ispartof><rights>Copyright John Libbey Eurotext 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14711605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parant, F</creatorcontrib><creatorcontrib>Ducluzeau, R</creatorcontrib><creatorcontrib>Lardet, G</creatorcontrib><creatorcontrib>Gagnieu, M-C</creatorcontrib><creatorcontrib>Moulsma, M</creatorcontrib><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><title>Annales de biologie clinique (Paris)</title><addtitle>Ann Biol Clin (Paris)</addtitle><description>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are &gt;25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Digoxin - blood</subject><subject>Digoxin - immunology</subject><subject>Drug Monitoring - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ultrafiltration</subject><issn>0003-3898</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KAzEYAHNQbG19BckLLCSbn816K8WqUOil9_Il-ZJGdpNlN4K-vQftaQ4DA3NH1owx0QjTmxV5XJZPxnhrhHggKy47zjVTa3La5Zp8iuU7ZXoAS8MMccRcFwrZ05sZS061zCnHFwrUXWEYMEekocy0XpHaVIYS01K35D7AsODTPzfkfHg979-b4-ntY787NpOSqvHgOqesbyH0rkepULAOWgccTRsCaql1r1vtVfDWaKcBuQQGngchg7FiQ57_stOXHdFfpjmNMP9cbmPiF1ebSpA</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Parant, F</creator><creator>Ducluzeau, R</creator><creator>Lardet, G</creator><creator>Gagnieu, M-C</creator><creator>Moulsma, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200311</creationdate><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><author>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-dac7c5bd2af9c9e45e307a2ca1e82ffe64669626d5fdb86c6ae14a0ad1f34f8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Digoxin - blood</topic><topic>Digoxin - immunology</topic><topic>Drug Monitoring - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ultrafiltration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parant, F</creatorcontrib><creatorcontrib>Ducluzeau, R</creatorcontrib><creatorcontrib>Lardet, G</creatorcontrib><creatorcontrib>Gagnieu, M-C</creatorcontrib><creatorcontrib>Moulsma, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Annales de biologie clinique (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parant, F</au><au>Ducluzeau, R</au><au>Lardet, G</au><au>Gagnieu, M-C</au><au>Moulsma, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</atitle><jtitle>Annales de biologie clinique (Paris)</jtitle><addtitle>Ann Biol Clin (Paris)</addtitle><date>2003-11</date><risdate>2003</risdate><volume>61</volume><issue>6</issue><spage>645</spage><pages>645-</pages><issn>0003-3898</issn><abstract>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are &gt;25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</abstract><cop>France</cop><pmid>14711605</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0003-3898
ispartof Annales de biologie clinique (Paris), 2003-11, Vol.61 (6), p.645
issn 0003-3898
language fre
recordid cdi_pubmed_primary_14711605
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Aged
Aged, 80 and over
Digoxin - blood
Digoxin - immunology
Drug Monitoring - methods
Female
Humans
Immunoglobulin Fab Fragments - therapeutic use
Male
Middle Aged
Ultrafiltration
title Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antidigoxin%20Fab%20fragments%20and%20digoxin%20monitoring:%20a%20challenge%20for%20the%20biologist&rft.jtitle=Annales%20de%20biologie%20clinique%20(Paris)&rft.au=Parant,%20F&rft.date=2003-11&rft.volume=61&rft.issue=6&rft.spage=645&rft.pages=645-&rft.issn=0003-3898&rft_id=info:doi/&rft_dat=%3Cpubmed%3E14711605%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14711605&rfr_iscdi=true